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Purpose. Oxaliplatin is a platinum-based chemotherapeutic agent demonstrating significant antitumor efficacy.Unlike conventional
anticancer agents which are immunosuppressive, oxaliplatin has the capacity to stimulate immunological effects in response to
the presentation of damage associated molecular patterns (DAMPs) elicited upon cell death. However, the effects of oxaliplatin
treatment on systemic immune responses remain largely unknown. Aims of this study were to investigate the effects of oxaliplatin
treatment on the proportions of (1) splenic T cells, B cells, macrophages, pro-/anti-inflammatory cytokines, gene expression of
splenic cytokines, chemokines, and mediators; (2) double-positive and single-positive CD4+ and CD8+ T thymocytes; (3) bone-
marrow hematopoietic stem and progenitor cells. Methods. Male BALB/c mice received intraperitoneal injections of oxaliplatin
(3mg/kg/d) or sterile water tri-weekly for 2 weeks. Leukocyte populations within the spleen, thymus, and bone-marrow were
assessed using flow cytometry. RT-PCR was performed to characterise changes in splenic inflammation-associated genes. Results.
Oxaliplatin treatment reduced spleen size and cellularity (CD45+ cells), increased the proportion ofCD4+, CD8+, andTreg cells, and
elevated TNF-𝛼 expression. Oxaliplatin was selectively cytotoxic to B cells but had no effect on splenic macrophages. Oxaliplatin
treatment altered the gene expression of several cytokines, chemokines, and cell mediators. Oxaliplatin did not deplete double-
positive thymocytes but increased the single-positive CD8+ subset. There was also an increase in activated (CD69+) CD8+ T cells.
Bone-marrow hematopoietic progenitor pool was demonstrably normal following oxaliplatin treatment when compared to the
vehicle-treatedcohort.Conclusion. Oxaliplatin does not cause systemic immunosuppression and, instead, has the capacity to induce
beneficial antitumor immune responses.
1. Introduction
It is well established that oxaliplatin can evoke the presen-
tation of damage associated molecular patterns (DAMPs)
within cancer cells to induce potent immunogenic cell death
[1–4]. Despite its immunostimulatory potential, the systemic
immune responses following oxaliplatin treatment remain
largely unknown. We have previously demonstrated that
oxaliplatin treatment causes the nuclear overexpression and
cytoplasmic translocation of the DAMP high-mobility group
box 1 (HMGB1), within the colon. However, despite the
induction of DAMPs, oxaliplatin treatment does not result
in gastrointestinal inflammatory responses. We hypothesised
that the lack of inflammation within the colon following
oxaliplatin treatment is due to tissue-specific responses,
rather than immunosuppression by this anticancer agent.
The gastrointestinal mucosa is continuously challenged
by a myriad of antigens, pathogens, nutrients, and ions and is
a prime target for cytotoxic insult by anticancer agents due to
its high proliferation rate [5, 6]. Given the constant exposure
to harmful antigens, the gastrointestinal immune system has
evolved a level of tolerance against pathogens and antigens
[6, 7]. Thus, bouts of inflammation in response to individual
stimuli would be detrimental to the host.
The spleen plays a major role in augmenting systemic
immune responses to blood borne pathogens and antigens,
as it is rich in antigen presenting cells, and effector lym-
phocyteswhich produce appropriate adaptive immunological
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responses [8, 9]. The thymus and bone marrow provide a
replenishing pool of leukocytes which migrate to lymphoid
organs such as the spleen uponmaturation. Currently, there is
minimal research documenting the immunological changes
within the spleen, thymus, and bone marrow following
oxaliplatin treatment; specifically, there is a paucity of studies
on the impact of oxaliplatin treatment on haematopoiesis.
The aims of this study were to investigate the effects of
oxaliplatin treatment on spleen size and leukocyte cellular-
ity and phenotype. The effects of oxaliplatin treatment in
polarising inflammatory cytokine responses were assessed.
Thymocytes and bone marrow hematopoietic progenitor and
stem cells were studied to determine their role in oxaliplatin-
induced changes in leukocytes.
2. Materials and Methods
2.1. Animals. Male, BALB/c mice (n=47, aged 5-7 weeks,
weighing 18-25g) were used in this study. Mice had access
to food and water ad libitum and were kept under a 12 hour
light/dark cycle in a well-ventilated room at a temperature
of 22∘C. Mice acclimatised for up to 1 week prior to the
commencement of in vivo intraperitoneal injections. All
efforts were made to minimise animal suffering, to reduce
the number of animals used and to utilise alternatives to in
vivo techniques, if available. All procedures in this study were
approved by the Victoria University Animal Experimentation
Ethics Committee (Ethics No: 15-011) and performed in
accordance with the guidelines of the National Health and
Medical Research Council Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes.
2.2. Oxaliplatin Treatment. Mice were separated into 2
cohorts (n=5-15/group): (1) vehicle (sterile water), (2) oxali-
platin (3mg/kg, Sigma-Aldrich, Australia). All mice received
intraperitoneal injections (maximum of 200𝜇l/injection)
using 26 gauge needles, tri-weekly for up to 14 days. Dosages
were calculated per body surface area as per previously pub-
lished method [10, 11]. We administer oxaliplatin for 2 weeks
as this is equivalent to the cumulative chemotherapeutic dose
given in humans. We have previously published data describ-
ing the neurotoxic effects of oxaliplatin following 2 weeks of
treatment [12, 13] and, thus, aimed to determine whether this
neurotoxicity is associated with systemic inflammation. Mice
were culled via cervical dislocation 14 days subsequent to
their first intraperitoneal injection, and spleen, thymus, and
bone marrow were harvested.
2.3. Flow Cytometry. To identify changes in immune cell
composition following oxaliplatin treatment, the spleen,
thymus, and bone marrow were harvested. Manual cell
suspensions of the spleen and thymus were performed. The
bonemarrowwas harvested using a syringe flush-outmethod
on both hind limbs from each animal. Cell suspensions
were centrifuged at 1500 rpm for 5 minutes at 4∘C and
resuspended in red blood cell lysis buffer (BD Biosciences,
USA) and incubated in the dark for 20 minutes. Samples
were centrifuged at 1500 rpm for 5 minutes at 4∘C. The
supernatant of each cell suspension was aspirated and the
pellet containing the immune cells was then resuspended in 1
ml of FACS buffer and filtered. Aliquots (10 𝜇l) of each cell
suspension were transferred into separate eppendorf tubes
containing 10 𝜇l of trypan blue. Manual cell counts were
performed using haemocytometer. Cell suspensions with
>90% cell viability were only then used for immunolabelling.
Cells were transferred appropriately to 96 U-bottom well
plates (BD Biosciences, USA) and were centrifuged at 1300
rpm for 3 minutes at 4∘C. Subsequent to centrifugation,
the 96 U-bottom well plates were then aspirated. A selec-
tion of cell surface antibodies was used to identify various
immune cell populations (Table 1). For intracellular labelling
of cytokines, spleen cell suspensions were permeabilised
using a CytoFix/Perm kit (BD Biosciences, USA) according
to manufacturer’s instructions. Furthermore, 30 𝜇l of each
antibody cocktail was loaded to appropriate wells and incu-
bated for 20 minutes at 4∘C. Subsequent to the incubation
period, cells were washed with 165 𝜇l of FACS buffer and
centrifuged at 1300 rpm for 3 minutes at 4∘C.The plates were
aspirated and cells within each well were resuspended in 200
𝜇l of FACS buffer. Cells were then transferred to FACS tubes.
BD Biosciences LSR II or FACS CANTO II flow cytometers
were used to collect 200,000 cells from each cell suspension.
Data were acquired using BD FACSDiva software v6.1
(BD Biosciences, USA), and analysis was conducted using
FlowJo (Tree Star, USA) or FACSDiva v6.1 software (BD
Biosciences, USA).The 7AADviability marker was not in our
flow cytometry antibody panels during acquisition since the
viability of our cellswere in excess of 90%; thus, we performed
exclusion gating to eliminate any dead cells and debris using
FSC and SSC gating. These settings have been confirmed
to be accurate using 7AAD backgating, a method published
previously [14].
2.4. RNA Isolation and RT2 Proﬁler PCR. Spleen tissue was
removed from vehicle-treated and oxaliplatin-treated mice
(n=5/group). Total RNAwas extracted using TRIzol (Invit-
rogen, Carlsbad, USA) and further purified using RNeasy
Mini columns (Qiagen, Hilden, Germany), including DNase
digestion to remove residual genomic DNA. The integrity of
all RNA samples was assessed on an Agilent 2100 Bioanalyzer
(Agilent Biotechnologies), setting the limit for inclusion in
the study as an RNA Integrity Number (RIN) of 9.0. The
concentration of individual RNA samples was measured
using a Qubit RNA BR Assay (Invitrogen) and RNA pools
were prepared for mRNA expression analysis by combining
equal quantities of RNA within each group. Gene expression
was investigated with the pathway specific RT2 Profiler
PCR Array “Mouse Cancer Inflammation and Immunity
Crosstalk” (Qiagen, Cat. no. PAMM-181Z), using 0.5 𝜇g
pooled RNA template, as described previously [15].
2.5. Statistical Analysis. Statistical analysis included the stu-
dent t-test or One-Way ANOVA with multiple comparisons
and Bonferroni’s post-hoc test using GraphPad Prism
v6.0 (GraphPad Software, USA). The data were represented
as mean ± standard error of the mean (SEM). Statistical
significance was defined where the P value was less than 0.05.
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Table 1: Antibodies used for flow cytometry experiments in this study.
Cells Primary antibody Conjugate Host species Dilution
Pan-leukocyte marker CD45 PerCP/Cy5.5 Mouse 1:400
Pan-T cell marker CD3 Alexa Fluor 488 Mouse 1:400
T cell receptor TCR𝛽 APC Rat 1:250
Granulocytes GR-1, CD11b PE-Cy7 Rat 1:100
Cytotoxic T cells CD8 Brilliant Violet 421 Rat 1:100
Helper T cells CD4 Brilliant Violet 500 Rat 1:100
Regulatory T cells Folate receptor 4 Alexa Fluor 647 Mouse 1:100
Activated T cells CD25 PE-Cy7 Mouse 1:100
Activated T cells CD69 APC-Cy7 Mouse 1:100
B cells B220 FITC Mouse 1:400
Macrophages CD11b, Ly6C, Ly6G,CD206, F4/80 PE Rat 1:200
Hematopoietic Stem and
Progenitor Cell CD34 FITC Mouse 1:100
Hematopoietic Stem and
Progenitor Cell c-Kit PE Mouse 1:100
Hematopoietic Stem and
Progenitor Cell Sca-1 PE-Cy7 Mouse 1:100
Hematopoietic Stem and
Progenitor Cell Lineage cocktail APC Mouse 1:100
Cytokines
IL-6 IL-6 APC Mouse 1:100
TNF-𝛼 TNF-𝛼 Brilliant Violet 510 Mouse 1:100
IL-10 IL-10 APC Mouse 1:100
TGF𝛽 TGF𝛽 Brilliant Violet 421 Mouse 1:100
3. Results
3.1. Oxaliplatin Treatment Decreases Spleen Mass. To deter-
mine toxicity of the spleen following oxaliplatin treatment we
measured weight (g). Oxaliplatin treatment caused a signif-
icant reduction in spleen mass (0.065g ± 0.004g, P<0.0001;
n=14) when compared to those obtained from the vehicle-
treated cohort (0.102g ± 0.003g; n=9) (Figures 1(a) and
1(a󸀠)). Furthermore, we determined cellularity with respect
to CD45+ cells using flow cytometry. A significant reduction
in the proportion of CD45+ leukocytes was noted following
oxaliplatin treatment (44.6 ± 4.7%, P<0.001; n=4) when
compared to the vehicle-treated group (84.4 ± 0.4%; n=4)
(Figure 1(b)).
3.2. Oxaliplatin Treatment Diﬀerentially Aﬀects CD4+, CD8+,
and Treg Populations within the Spleen. To determine any
changes in the proportions of CD4+ and CD8+ T cells,
we gated on CD3+CD4+/CD8+/GR-1−/FOLR4+ expressing
cells and cytokines (pro-inflammatory: IL-6 and TNF-𝛼;
anti-inflammatory: IL-10 and TGF𝛽). Oxaliplatin treatment
caused a significant increase in the proportion of CD4+ T
cells (26.6± 1.1%, P<0.01; n=5)when compared to the vehicle-
treated cohort (20.8 ± 0.6%; n=5) (Figure 2(a)). Oxaliplatin
treatment also caused a significant increase in the proportion
of CD8+ T cells (44.0 ± 0.9%, P<0.01; n=9) when compared
to the vehicle-treated group (38.5 ± 0.7%; n=4) (Figure 2(b)).
Furthermore, a significant reduction in the proportion of
regulatory T cells (Tregs) was noted following oxaliplatin
treatment (43.4 ± 1.3%, P<0.01; n=5) when compared to the
vehicle-treated cohort (54.2 ± 0.7%; n=5) (Figure 2(c)).
No changes in IL-6 expression of T cells from the spleen
was observed between the vehicle-treated (0.20 ± 0.01%;
n=9) and the oxaliplatin-treated mice (1.80 ± 0.97%; n=14)
(Figure 2(d)). However, a significant increase in TNF-𝛼
was observed in the oxaliplatin-treated group (17.9 ± 4.6%;
P<0.01; n=14) when compared to the vehicle-treated cohort
(3.5 ± 1.4%; n=9) (Figure 2(d)). There were no changes to
anti-inflammatory cytokines between vehicle-treated (IL-10:
0.10 ± 0.03%; n=9; TGF-𝛽: 0.5 ± 0.2%; n=9) and oxaliplatin-
treated mice (IL-10: 0.14 ± 0.03%; n=14; TGF-𝛽: 0.39 ± 0.06%;
n=14) (Figure 2(e)).
To determine whether T cells were activated, we gated on
CD4+, CD8+, and FOLR4+ expressing cells double-positive
for the activation markers CD25 and CD69. There were no
significant differences in the proportion of activated CD3+
CD4+ CD25+ T cells following oxaliplatin treatment (0.04
± 0.02%; n=5) when compared to the vehicle-treated cohort
(0.08 ± 0.02%; n=5) (Figure 3(a)). Furthermore, there were
no significant differences in the proportion of activated CD3+
CD4+ CD69+ T cells following oxaliplatin treatment (0.42
± 0.03%; n=5) compared to vehicle-treated control (0.4 ±
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Figure 1: Eﬀects of oxaliplatin on spleen mass and cellularity. To investigate toxicity of the spleen following oxaliplatin treatment we measured
weight (g). Oxaliplatin treatment caused a significant reduction in spleen mass when compared to those obtained from the vehicle-treated
cohort (a, a󸀠). A significant reduction in the proportion of CD45+ leukocytes was observed following oxaliplatin treatment when compared
to the vehicle-treated group (b). ∗ ∗ ∗P<0.001; ∗ ∗ ∗∗P<0.0001.
0.03%; n=5) (Figure 3(b)). Similarly, no significant differences
in the proportion of activated CD3+ CD8+ CD25+ T cells
were observed following oxaliplatin treatment (0.08 ± 0.04%;
n=5) when compared to the vehicle-treated cohort (0.18 ±
0.04%; n=5) (Figure 3(c)). Conversely, a significant increase
in the proportion of activated CD3+ CD8+ CD69+ T cells
was noted following oxaliplatin treatment (0.23 ± 0.05%,
P<0.01; n=5) when compared to the vehicle-treated cohort
(0.1 ± 0.001%; n=5) (Figure 3(d)). Tregs were identified as
CD4+/CD25+/FOLR4+ cells. CD4+ cells express high levels
of FOLR4 as well as Foxp3 and, thus, FOLR4 can be used
in substitute to Foxp3 [16–19]. No significant differences in
the proportion of activated CD4+ FOLR4+ CD25+ T cells
were observed following oxaliplatin treatment (0.18 ± 0.06%;
n=5) when compared to the vehicle-treated control (0.18 ±
0.05%; n=5) (Figure 3(e)). However, a significant increase in
the proportion of activated CD4+ FOLR4+ CD69+ T cells
was observed following oxaliplatin treatment (2.69 ± 0.21%,
P<0.01; n=5) when compared to the vehicle-treated cohort
(1.7 ± 0.15; n=5) (Figure 3(f)).
3.3. Oxaliplatin Treatment Decreases B Cell Proportions in the
Spleen. B cells were identified by gating on CD45+ TCR𝛽−
B220+ cells. Oxaliplatin treatment caused a significant reduc-
tion in the proportion of B cells (23.1 ± 2.4%, P<0.0001; n=4)
when compared to the vehicle-treated cohort (49 ± 0.7%;
n=4) (Figure 3(g)).
3.4. Oxaliplatin Has No Eﬀects on Macrophage Phenotypes
or Pro-/Anti-Inﬂammatory Cytokines in the Spleen. To deter-
mine changes in immune cell populations within the spleen
BioMed Research International 5
vehicle oxaliplatin
CD3+ CD4+
0
10
20
30
40
%
∗∗
(a)
CD3+ CD8+
vehicle oxaliplatin
0
10
20
30
40
50
%
∗∗
(b)
vehicle oxaliplatin
CD3+ CD4+ FOLR4+
0
20
40
60
%
∗∗
(c)
IL-6 TNF-
Pro-inflammatory cytokines
vehicle
oxaliplatin
0
10
20
30
40
50
%
 T
 ce
lls
∗∗
(d)
IL-10 TGF
Anti-inflammatory cytokines
vehicle
oxaliplatin
0.0
0.5
1.0
1.5
2.0
2.5
%
 T
 ce
lls
(e)
Figure 2: Eﬀects of oxaliplatin on the proportion of T cell populations and pro-/anti-inﬂammatory cytokines within the spleen. To determine
any changes in the proportions of CD4+ and CD8+ T cells and Tregs we gated on CD3+CD4+/CD8+/GR-1−/FOLR4+ events. Proinflammatory
and anti-inflammatory cytokines were gated on IL-6, TNF-𝛼, IL-10, and TGF𝛽 events. Oxaliplatin treatment caused a significant increase in
the proportion of CD3+ CD4+ and CD3+ CD8+ T cells when compared to the vehicle-treated group (a, b). Conversely, oxaliplatin treatment
caused a significant decrease in the proportion of CD3+ CD4+ FOLR4+ T cells when compared to the vehicle-treated group (c). No changes
in IL-6 expression were observed between the vehicle-treated and the oxaliplatin-treated mice; however, a significant increase in TNF-𝛼was
noted in the oxaliplatin-treated group when compared to the vehicle-treated cohort (d). No changes in either anti-inflammatory cytokines
were observed between the vehicle-treated and oxaliplatin-treated mice (e). Vehicle: n=5-9; oxaliplatin: n=5-14; ∗∗P<0.01.
we profiled M1/M2 macrophages as well as the expression of
proinflammatory (IL-6 and TNF-𝛼) and anti-inflammatory
(IL-10 and TGF𝛽) cytokines. To determine any changes in
the proportions of proinflammatory and anti-inflammatory
macrophages and cytokines (pro-inflammatory: IL-6 and
TNF-𝛼; anti-inflammatory: IL-10 and TGF𝛽), a set of gating
strategies were used. M1 macrophages were gated based
on CD45+ CD11B+, Ly6G+ Ly6C+, CD11C+ MHC-II+, and
CD206+ expressing cells. M2 macrophages were gated based
on: CD45+ CD11B+, Ly6G+ CD45+, CD11B+ MHC-II+, and
CD206+ expressing cells. There were no differences in M1
macrophages amongst the vehicle-treated (90.3 ± 1.9%; n=6)
and oxaliplatin-treated (88.4 ± 2.0%; n=14) groups (Fig-
ure 4(a)). Furthermore, no differences were observed in
M2 macrophages amongst the vehicle-treated (9.6 ± 1.5%;
n=6) and oxaliplatin-treated groups (11.5 ± 2.0%; n=14)
(Figure 4(a)). Consequently, there were no changes in M1
cytokines between vehicle-treated (IL-6: 0.05 ± 0.01%; n=9;
TNF-𝛼: 0.91± 0.29%; n=9) and oxaliplatin-treatedmice (IL-6:
0.61± 0.34%, n=14; TNF-𝛼: 0.98± 0.45%; n=14) (Figure 4(b)).
Moreover, there were no differences inM2 cytokines amongst
the vehicle-treated (IL-10: 2.7 ± 1.07%; n=9; TGF𝛽: 2.1% ±
0.84%; n=9) and oxaliplatin-treated mice (IL-10: 2.5 ± 0.80%;
n=14; TGF𝛽: 2.7 ± 1.2%; n=14) (Figure 4(c)).
3.5. Eﬀects of Oxaliplatin on Inﬂammation-Associated Genes
in the Spleen. To determine changes in expression of
inflammation-associated genes in the spleen, RT-PCR was
performed using RT2− PCR-arrays. Oxaliplatin treatment
caused the upregulation of the cytokine colony stimulating
factor 1 (Csf-1; 1.53 fold change) but a decrease in Csf-2
(-1.64 fold change), IL-1𝛽 (-2.00 fold change), IL-10 (-1.62
fold change), and IL-12𝛽 (-2.97 fold change) (Figure 5(a)).
Furthermore, oxaliplatin treatment caused the upregula-
tion of the C-C motif chemokine receptor 2 (Ccr2) gene
(1.71 fold change) but downregulated the genes Ccr5 (-
1.63 fold change), C-C motif chemokine ligand Ccl5 (-1.77
fold change), Ccl22 (-1.68 fold change), and Ccr9 (-1.61
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Figure 3: Eﬀects of oxaliplatin on the proportion of activated T cell populations and B cells within the spleen. To determine any changes in the
proportions of activatedCD4+ and CD8+ T cells, we gated on CD4+ CD25+ CD69+, CD8+ CD25+ CD69+, and CD4+ FOLR4+ CD25+ CD69+
events. Oxaliplatin treatment did not cause any changes in the proportion of activated CD4+ T cells (a, b). However, a significant increase in
the proportion of CD8+ CD69+, but not CD8+ CD25+ was observed following oxaliplatin treatment when compared to the vehicle-treated
group (c, d). Oxaliplatin caused a significant increase in the proportion of CD4+ FOLR4+ CD69+, but not CD4+ FOLR4+ CD25+ Tregs, when
compared to the vehicle-treated group (e, f). B cells were identified by gating on CD45+ TCR𝛽− B220+ cells. Oxaliplatin treatment caused
a significant reduction in the proportion of B cells when compared to the vehicle-treated cohort (g). Vehicle: n=5-9; oxaliplatin: n=5-14;
∗∗P<0.01.
fold change) (Figure 5(b)). Furthermore, oxaliplatin treat-
ment downregulated the genes Activation-induced cytdidine
deaminase (Aicda; -2.01 fold change), Bcl-2-like 1 (Bcl2l1;
-2.75 fold change), and cytotoxic T lymphocyte-associated
protein 4 (CTLA-4; -1.96 fold change) (Figure 5(c)). Most
genes represented on the array showed no detectable differ-
ence in expression (less than 1.5 fold) when comparing the
oxaliplatin-treated group to the vehicle-treated group.
3.6. Oxaliplatin Treatment Increases CD8+ Single-Positive
ymocytes with No Eﬀects on CD4+, or CD4+ CD8+ Double-
Positive Populations. To assess changes in the proportions
of double-positive and single-positive thymocytes, cells were
gated by CD4+ CD8+ populations. No significant differences
were observed in the proportion of double-positive CD4+
CD8+ thymocytes following oxaliplatin treatment (63.8 ±
5.7%; n=5) when compared to the vehicle-treated cohort
(71.4 ± 4.5%; n=5) (Figure 6(a)). Furthermore, no significant
differences were observed in the proportion of single-positive
CD4+ thymocytes following oxaliplatin treatment (8.0 ±
1.06%; n=5) when compared to the vehicle-treated cohort (9.7
± 0.3%; n=5) (Figure 6(b)). Oxaliplatin treatment caused a
significant increase in the proportion single-positive CD8+
thymocytes following oxaliplatin treatment (14.4 ± 2.4%;
BioMed Research International 7
vehicle oxaliplatin
M1/M2
M1
M2
0
50
100
150
%
 M
ac
ro
ph
ag
es
(a)
IL-6 TNF-
M1 Cytokines
vehicle
oxaliplatin
0
1
2
3
4
5
%
 M
ac
ro
ph
ag
es
(b)
IL-10 TGF
M2 Cytokines
vehicle
oxaliplatin
0
5
10
15
20
%
 M
ac
ro
ph
ag
es
(c)
Figure 4:Eﬀects of oxaliplatin on the proportion ofM1/M2 phenotypes and pro-/anti-inﬂammatory cytokines within the spleen. To determine any
changes in the proportions of pro-inflammatory and anti-inflammatory macrophages, a set of gating strategies were used. M1 macrophages
were gated on CD45+ CD11B+, Ly6G+ Ly6C+, CD11C+ MHC-II+, CD206+ CD45+ cells. M2 macrophages were gated on: CD45+ CD11B+,
Ly6G+ CD45+, CD11B+MHC-II+, CD206+ CD45+ cells. To investigate any changes to pro-inflammatory cytokine expression cells were gated
on their expression of M1 phenotypes versus IL-6, TNF-𝛼, IL-10 and TGF𝛽. To determine the expression of anti-inflammatory cytokines
fromM2macrophages cells were gated on their phenotype versus IL-10 or TGF-𝛽. No differences inM1macrophages were observed between
the vehicle-treated and oxaliplatin-treated animals (a). No differences were observed in M2 macrophages amongst the vehicle-treated and
oxaliplatin-treated animals (a). No changes in M1 or M2 cytokines were observed between the vehicle-treated and oxaliplatin-treated mice
(b, c). Vehicle: n=9; oxaliplatin: n=14.
8 BioMed Research International
Cfs1 Cfs2
Cytokines
vehicle
oxaliplatin
upregulated
downregulated
−2
−1
0
1
2
Fo
ld
 ch
an
ge
(a)
Ccr2 Ccr9 Ccl5 Ccl22
Chemokines
vehicle
oxaliplatin
upregulated
downregulated
−2
−1
0
1
2
Fo
ld
 ch
an
ge
(b)
Aicda Bcl2l1 CTLA-4
Mediators
vehicle
oxaliplatin
upregulated
downregulated
−3
−2
−1
0
1
2
Fo
ld
 ch
an
ge
(c)
Figure 5: Eﬀects of oxaliplatin on inﬂammation-associated genes within the spleen. RT2 profiler arrays were used to determine changes
in expression of inflammation-associated genes. Oxaliplatin treatment resulted in upregulation of Csf1 and downregulation of Csf2 (a).
Oxaliplatin treatment caused the upregulation of Ccr2 and downregulation of Ccr9, Ccl5 andCcl22 gene expression (b). Oxaliplatin treatment
downregulated mRNA expression levels of Aicda, Bcl2l1 and CTLA-4 (c).
n=5) when compared to the vehicle-treated cohort (7.4 ±
0.6%; n=5) (Figure 6(c)).
3.7. Oxaliplatin Treatment Has No Demonstrable Eﬀects on
Bone Marrow Hematopoietic Stem and Progenitor Cells. To
ascertainwhether changes in the proportions of bonemarrow
hematopoietic stem and progenitor cells, cells were gated
on Lin−/CD117+/Sca-1+ cells. No significant differences were
observed in the proportion of Lin−/CD117+/Sca-1+ cells
following oxaliplatin treatment (0.2 ± 0.05%; n=5) when
compared to the vehicle-treated cohort (0.24 ± 0.02%; n=5)
(Figure 6(d)).
4. Discussion
This study is amongst the first to determine systemic immune
responses following oxaliplatin treatment in the mouse
spleen, thymus, and bone marrow. Our data show that
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Figure 6: Eﬀects of oxaliplatin treatment on T cell populations within the thymus and progenitor cells in the bone marrow. To determine any
changes in the proportions of double-positive and single-positive thymocytes, we gated on CD4+ CD8+ events. No significant changes were
observed in the proportion of double-positive CD4+ CD8+ thymocytes following oxaliplatin treatmentwhen compared to the vehicle-treated
cohort (a). No significant differences were observed in the proportion of single-positive CD4+ thymocytes following oxaliplatin treatment
when compared to the vehicle-treated cohort (b). Oxaliplatin treatment caused a significant increase in the proportion single-positive CD8+
thymocytes following oxaliplatin treatment when compared to the vehicle-treated cohort (c). To determine any changes in the proportions
of bone marrow hematopoietic stem and progenitor cells, we gated on Lin−/CD117+/Sca-1+ events. There were no significant differences in
the proportion of Lin−/CD117+/Sca-1+ cells following oxaliplatin treatment when compared to the vehicle-treated cohort (d). N=5/group;
∗∗P<0.01.
oxaliplatin does not cause systemic immunosuppression and,
in fact, can skew proinflammatory immune responses. The
presentation of DAMPs following oxaliplatin treatment has
previously been shown to induce immunogenic cell death
in colorectal tumor cell lines [1]. Despite the potential to
induce immunogenic cell death, oxaliplatin did not cause any
inflammatory responses within the gastrointestinal tract [15].
Thus, it was hypothesised that this may be due to tissue-
specific immune responses within the gastrointestinal tract
and that immunological responses may differ systemically.
The spleen functions are to clear aged erythrocytes,
filter blood-borne pathogens, antigens, and foreignmaterials,
and play a major role in augmenting appropriate systemic
immune responses [20, 21]. As the spleen receives a large
volume of blood, this organ may be particularly vulnerable to
platinum-based anticancer agents or, perhaps, may be a site
for generating immunological responses to chemotherapy. In
this study, we have shown that oxaliplatin treatment caused
a significant decrease in spleen size and in the proportion of
CD45+ immune cells. Previous work investigating spleen size
following anticancer chemotherapy is conflicting. Computed
tomography imaging of spleens from patients undergoing
carboplatin/paclitaxel or cisplatin/etopisode chemotherapy
and concomitant radiotherapy for nonsmall cell lung car-
cinoma demonstrate a decrease in spleen volume in 66%
and 79% of patients respectively [22]. Patient spleen size
is typically estimated by multiplying organ length by width
and height. Furthermore, splenomegaly has been observed in
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colorectal cancer patients receiving oxaliplatin in a FOLFOX
regimen [23–25]. Aside from our data, it is unclear how
platinum-based drugs affect spleen size when given as a single
agent and, thus, further work is required to understand these
changes in organ size.
Despite a reduction in spleen size and cellularity fol-
lowing oxaliplatin treatment, the proportions of overall
CD4+ and CD8+ T cells were increased in this cohort
when compared to the vehicle-treated group. Helper CD4+
T cells play a role in adaptive immunity by conditioning
the environment and, essentially, modulating the activity of
other immune cells through cytokine production such as
polarizing DCs that can perform cross-presentation to CD8+
T cells [26, 27].There are limited studies regarding the effects
of oxaliplatin and the predecessor platinum-based agents
on CD4+ T cells. Studies investigating the effects of other
anticancer agents such as cyclophosphamide have shown that
this drug can selectively deplete Tregs and restore effector T
cell function which is imperative for antitumor responses, as
well as mounting appropriate immune responses to antigens
[28, 29]. Previous work has shown that cisplatin given in
combination with a TLR9 agonist CpG and a pan-human
leukocyte antigen DR binding epitope enhances systemic
CD4+ T cell responses against papillomavirus 16 E7 tumors
[30]. Moreover, cisplatin treatment also leads to an increase
in CD4+ T and CD8+ T cell-mediated immune responses
leading to nephrotoxicity [31]. These data demonstrate the
immunostimulatory potential of platinum-based drugs to
mount anti-tumor responses but highlight the fact that they
may also mediate tissue injury.
CD8+ T cells play a role in cell-mediated cytotoxicity
through cytokine release, death ligand stimulation, and per-
forin/granzyme B-mediated pathways. In this present study,
we have shown that oxaliplatin treatment increases the overall
proportion of CD8+ T cells, and enhances CD8+ T cell acti-
vation as demonstrated by CD69 expression [32–34]. These
data show that CD8+ T cells have been primed and activated
as a result of appropriate antigen-presentation. Our study is
in line with earlier reports which had shown that increased
CD8+ T cell activation and function following oxaliplatin
treatment in peripheral blood and colon cancer cell lines [1,
2]. Previous work assessing peripheral neuropathy following
oxaliplatin treatment in C57BL/6J mice has demonstrated an
increase in circulating CD8+ T cells [35]. Although CD8+
T cells were not measured in the blood, T cells primed
and activated within the spleen migrate to sites of damage.
Furthermore, the addition of cisplatin to an immunotherapy
vaccine comprised of calreticulin and papillomavirus 16 E7
antigens for the treatment of cervical cancer enhances CD8+
T cell responses [36]. The activation states of CD8+ T cells
are further supported by the downregulation of CTLA-4 gene
expression observed in this study. This gene codes for the
CTLA-4 inhibitory ligand which is a negative regulator of
T cell function [37–39]. Thus, it is becoming well known
that platinum-based agents can induce T cell responses that
would be beneficial for cancer treatment; however, it is
currently unknown where these CD8+ T cells will migrate
from the spleen in response to oxaliplatin treatment and
whether a subset of these cells are MAIT cells (requires
tetramer which is unavailable to us) and this requires
further work.
Tregs are well known for their immunosuppressive roles
in maintaining self-tolerance and in controlling inflamma-
tory responses [40, 41]. In this study, we showed that oxali-
platin treatment caused a reduction in the proportion of Tregs
when compared to the vehicle-treated cohort. However, the
proportion of activated Tregs following oxaliplatin treatment
increased. Our findings are in contrast to a study which
demonstrated an increase of Tregs in blood samples from
patients receiving combined oxaliplatin and 5-fluorouracil
treatment for CRC [42]. It is unclear why a decrease in Tregs
is observed following oxaliplatin treatment, but the addition
of 5-flourouracil to the treatment may induce differential
immune responses [43–45].
Oxaliplatin has demonstrated immunostimulatory
potential, and we aimed to investigate whether treatment
with this drug could stimulate cytokine production in
the spleen. As both cancer and oxaliplatin treatment
have immunomodulatory properties, it is important to
investigate their impact individually before studying them
in combination. In this study, we observed the increased
expression of the proinflammatory cytokineTNF-𝛼 in splenic
T cells. Most research has demonstrated that platinum-based
drugs induce TNF-𝛼 production by nonimmune cells.
Previous studies showed that oxaliplatin treatment causes
astrocyte and glial cell activation and the production of TNF-
𝛼 in a rat model of peripheral neuropathy [46]. Additionally,
an increase in TNF-𝛼 expression by spinal glial cells has also
been observed in amodel of oxaliplatin-induced neuropathic
cold allodynia [47]. In addition to this, an increase in TNF-𝛼
has been previously described following cisplatin treatment
in kidney proximal tubule and epithelial cells [48, 49].
It is known that TNF-𝛼 can alter neuronal function and
induce cell death via the extrinsic apoptosis pathway (death
receptor-mediated cascades) [50]. TNF-𝛼 binding to the
TNF superfamily receptor recruits the caspases 8/10 to
the death domain docking site and initiates the apoptotic
cascade for the cleavage of caspase-3. The extrinsic and
intrinsic apoptotic pathways can have some crossover and
it is unclear whether death receptor stimulation has played
a role in initiating the apoptotic cascade. We have found
that platinum from oxaliplatin accumulates within the brain
(unpublished observation). Oxaliplatin is a bulky drug
that was originally thought to be too big to pass through
the blood brain barrier. However, it is well known that
proinflammatory cytokines can alter blood-brain barrier
permeability which could allow for oxaliplatin accumulation
[51–53]. Cytokine-mediated reduction in blood-brain barrier
integrity could be implicated in the platinum accumulation
within the brain; however, further work is required to
elucidate this concept. No differences in the expression
of the anti-inflammatory cytokines IL-10 and TGF𝛽 was
observed following oxaliplatin treatment. This suggests
that no anti-inflammatory responses are being initiated to
counteract the increased proportion of activated CD4+ and
CD8+ T cells and TNF-𝛼 production.
We have shown that oxaliplatin is particularly cytotoxic
to splenic B cells and caused the downregulation of the Aicda
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gene expression, which plays a role B cell proliferation an Ig
class-switching [54, 55]. Within the spleen, B cells capture
antigens within the blood though complement receptors,
and can initiate T cell-dependent/independent responses
[56]. Research has shown that B cells can impede T cell
activation by expressing IgA, IL-10, and programmed cell
death ligand 1 (PD-L1) and by promoting T cell conversion
to Tregs [57–61]. The overall reduction in B cells and Aicda
following oxaliplatin treatmentmay affect IgA, IL-10, andPD-
L1 production and, thus, enable optimal T cell activation. As
spleen mass was significantly reduced following oxaliplatin
treatment despite strong T cell responses, the depletion of
B cells may account for the change in organ size. It should
be noted that we have not investigated whether oxaliplatin
treatment affects the connective tissue or the red pulp of the
spleen, as this would also have an impact on organ size.
Macrophages within the spleen play a role in antigen
recognition, processing and presentation to T cells, to ulti-
mately mount an appropriate immune response [62, 63]. In
this study, we have shown that oxaliplatin treatment has
no effects on the proportion of M1/M2 macrophages, or
their proinflammatory and anti-inflammatory cytokines. M1
macrophages produce the proinflammatory cytokines IL-
6 and TNF-𝛼 upon activation, whereas the M2 phenotype
expresses the anti-inflammatory cytokines IL-10 and TGF𝛽
[64, 65]. Splenic macrophages are in close contact with T cells
and, thus, their location favours rapid antigen presentation
[66, 67]. Whether changes in macrophage cytokine profiles
have occurred in earlier stages remains unknown, but the
increase in activated T cells suggests sufficient antigen pre-
sentation has occurred.
In addition, we show that oxaliplatin treatment differ-
entially affects chemokine receptors and ligand expression
within the spleen. Oxaliplatin treatment caused an increase
inCcr2 expression. Ccr2 is highly expressed onmacrophages,
and ligation by Ccl2 induces the recruitment of peripheral
monocytes during infectious and inflammatory conditions
[68]. As there were no changes in Ccl2 expression despite
upregulated Ccr2 within the spleen following oxaliplatin
treatment, this may explain why no changes were observed
in the proportion of splenic macrophages. Elevated Ccr2
and Ccl2 expression have been previously observed in the
dorsal root ganglia following the administration of another
anticancer agent, paclitaxel, and this was positively correlated
with peripheral neuropathy [69]. The effects of oxaliplatin
treatment on splenic macrophages largely remain unknown
and, thus, it is difficult to compare results from our current
study. Furthermore, in our current study we demonstrated
that oxaliplatin treatment increases Csf-1 expression within
the spleen. Csf-1 plays a role in macrophage maturation, pro-
liferation and survival [70, 71].This cytokine is produced by a
number of cells, including but not limited to, macrophages, T
cells, tumor cells, epithelial cells, and endothelial cells [72, 73].
Proinflammatory cytokines such as IL-1𝛽, IL-6, and TNF-𝛼
can also stimulate the upregulation of Csf-1 [72]. A number
of studies have demonstrated the importance of Csf-1 and
its effects on antigen presenting cells and T cell-mediated
immunity [74–77]. Csf-1 is now given adjuvantly with
the anticancer chemotherapeutics oxaliplatin, gemcitabine,
levofolinate, docetaxel, and 5-fluorouracil [78, 79]. Thus, the
increase in Csf-1 following oxaliplatin treatment may also
potentiate T-cell mediated immunity. Furthermore, Csf-2 is
a potent stimulator of granulocytes and lymphocytes [80].
However, oxaliplatin treatment appeared to downregulate
its expression within the spleen. Csf-2 has the capacity to
stimulate both Th1 and Th2 responses [81]. Given that its
expression at the mRNA level is downregulated this may
impact the production of other cytokines. IL-1𝛽 and IL-12𝛽
are proinflammatory cytokines which can potentiate T cell
responses [82–84]. The gene expressions of both cytokines
were reduced following oxaliplatin treatment, despite robust
T cell responses observed within the spleen. Leukocytes
do not contain intracellular cytokine reserves and, thus,
their production is regulated transcriptionally [85]. As strong
T cell responses were observed within the spleen, it is
unclear whether changes at the mRNA level for IL-1𝛽 and
IL-12𝛽 had occurred at an earlier stage during oxaliplatin
treatment. Future studies would seek to measure IL-12𝛽
in purified DCs to determine the source of these changes.
Similarly, reduced IL-10 mRNA expression was detected
following oxaliplatin treatment, although no changes were
observed in intracellular cytokine expression within the
spleen from flow cytometry experiments. Similarly, IL-
1𝛽 and IL-12𝛽 were also shown to be downregulated in
the colon of these mice following oxaliplatin treatment
[15].
Moreover, Ccr5, Ccl5, andCcl22 play a role in lymphocyte
trafficking [86, 87]. It is unclear whether the downregulation
of these ligands will impact T cell migration, despite their
proportional increase and activated states in the spleen. Of
interest, we also noted Ccl5 and Ccl22 were downregulated
in the colon [15]. Furthermore, oxaliplatin treatment reduced
Ccr9 expression within the spleen. Ccr9 is typically involved
in lymphocytemigration and cell survival, but it has also been
implicated in antiapoptotic cascades in several pathological
conditions [88–90]. The downregulation of this chemokine
receptor following oxaliplatin treatmentmay therefore enable
apoptotic signaling cascades. Oxaliplatin treatment also led
to a reduction in Bcl2l1 expression, a gene involved in
antiapoptotic cascades [91, 92]. The decreased expression of
Ccr9 and Bcl2l1 may contribute to spleen toxicity following
oxaliplatin treatment.
Our current work has shown that oxaliplatin treatment
increases the proportion of single-positive CD8+ thymocytes,
with no effect on double-positive CD4+ CD8+ thymocytes,
or single-positive CD4+ T cells. In the thymus, lymphoid
progenitors develop T cell receptor expression and become
double-positive for CD4+ and CD8+ T cells [93]. Within
the medullary region of the thymus, epithelial cells present
MHC-I and MHC-II molecules to double-positive T cells.
Thymocytes will then differentiate into single-positive CD4+
T cells or CD8+ T cells if they respond to MHC-II or
MHC-I molecules, respectively [93]. Upon single-positive
selection, these thymocytes migrate to secondary locations
such as the spleen and lymph nodes [94, 95]. The increase in
single-positive CD8+ thymocytes following oxaliplatin may
suggest the enhanced recruitment of cytotoxic T cells to the
periphery.
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Furthermore, our data has shown that oxaliplatin does
not negatively impact the bone marrow hematopoietic stem
cell progenitor pool. There is limited research demonstrat-
ing the effects of oxaliplatin treatment on bone marrow
progenitors. However, an indirect measure of bone marrow
suppression caused by oxaliplatin is the onset of thrombo-
cytopenia. Sensitivity reactions to oxaliplatin treatment have
been previously associated with immune thrombocytopenia
which is the Ig-mediated destruction of platelets thought to
be caused by mild bone marrow suppression [96, 97]. We did
not measure platelets in this study, but as the proportion of
bone marrow progenitors from the oxaliplatin-treated group
was similar to the vehicle-treated cohort, it does not appear
oxaliplatin is immunosuppressive.
Whilst we have demonstrated that oxaliplatin-treatment
can alter systemic immune responses in cancer na¨ıve mice,
our future studies will investigate the immune responses to
oxaliplatin in combination with a xenograft animal model.
It is well known that chemotherapeutic drugs and cancers
can modulate immune responses, so it is important to
elucidate their effects on the immune system exclusively, and
in combination.
5. Conclusion
The data provide evidence that oxaliplatin can induce ben-
eficial antitumor immune responses and that it is not an
immunosuppressive agent. Our data also reveals tissue-
specific immunological responses to oxaliplatin treatment.
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